Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets-Reference-Cited by-同舟云学术

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

Published:2020-11-16 Issue:12 Volume:1 Page:1204-1217
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Bhardwaj Nina^ORCID,Friedlander Philip A.,Pavlick Anna C.,Ernstoff Marc S.^ORCID,Gastman Brian R.,Hanks Brent A.,Curti Brendan D.,Albertini Mark R.,Luke Jason J.,Blazquez Ana B.,Balan Sreekumar^ORCID,Bedognetti Davide,Beechem Joseph M.,Crocker Andrea S.,D’Amico Leonard,Danaher Patrick^ORCID,Davis Thomas A.,Hawthorne Thomas,Hess Bruce W.,Keler Tibor,Lundgren Lisa,Morishima Chihiro,Ramchurren Nirasha,Rinchai Darawan^ORCID,Salazar Andres M.,Salim Bob A.,Sharon Elad,Vitale Laura A.,Wang Ena,Warren Sarah,Yellin Michael J.,Disis Mary L.,Cheever Martin A.,Fling Steven P.^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-020-00143-y.pdf

Reference58 articles.

1. Si, Z., Hersey, P. & Coates, A. S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 6, 247–255 (1996).

2. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).

3. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).